Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.76 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.76 |
| ▸ | HSD11B2 | P80365 | 3/20 | 0.76 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.76 |
| ▸ | HIF1A | Q16665 | 7/20 | 0.72 |
| ▸ | LMNA | P02545 | 6/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.72 |
| ▸ | SHBG | P04278 | 5/20 | 0.72 |
| ▸ | SERPINA6 | P08185 | 5/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.72 |
| ▸ | TSHR | P16473 | 3/20 | 0.72 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.72 |
| ▸ | MAPT | P10636 | 3/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.72 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.72 |
| ▸ | BLM | P54132 | 1/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.72 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.72 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.72 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20058563 | 1.00 | SMN1; SMN2 (0.76) | SMN1; SMN2NR3C2HSD11B2HSD11B1HIF1A | |
| SCHEMBL13752954 | 1.00 | SMN1; SMN2 (0.76) | SMN1; SMN2NR3C2HSD11B2HSD11B1HIF1A | |
| SCHEMBL10185506 | 1.00 | SMN1; SMN2 (0.76) | SMN1; SMN2NR3C2HSD11B2HSD11B1HIF1A | |
| SCHEMBL15920491 | 1.00 | SMN1; SMN2 (0.76) | SMN1; SMN2NR3C2HSD11B2HSD11B1HIF1A | |
| SCHEMBL3362406 | 1.00 | SMN1; SMN2 (0.76) | SMN1; SMN2NR3C2HSD11B2HSD11B1HIF1A | |
| SCHEMBL619054 | 1.00 | SMN1; SMN2 (0.76) | SMN1; SMN2NR3C2HSD11B2HSD11B1HIF1A | |
| SCHEMBL24900243 | 1.00 | SMN1; SMN2 (0.76) | SMN1; SMN2NR3C2HSD11B2HSD11B1HIF1A | |
| SCHEMBL14525631 | 1.00 | SMN1; SMN2 (0.76) | SMN1; SMN2NR3C2HSD11B2HSD11B1HIF1A | |
| SCHEMBL20058468 | 1.00 | SMN1; SMN2 (0.76) | SMN1; SMN2NR3C2HSD11B2HSD11B1HIF1A | |
| SCHEMBL619055 | 1.00 | SMN1; SMN2 (0.76) | SMN1; SMN2NR3C2HSD11B2HSD11B1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372267-A1 | AFFINITY MEDICANT CONJUGATE | Califia Pharma Inc. (US) | 2023-11-23 | — | — | US | disclosed |
| EP-4257186-A2 | AFFINITY MEDICANT CONJUGATES | AF Chemicals LLC (US) | 2023-10-11 | — | — | EP | disclosed |
| US-20230212113-A1 | AFFINITY ILLUDOFULVENE CONJUGATES | AF Chemicals, LLC, (US) | 2023-07-06 | — | — | US | disclosed |
| US-11591295-B2 | Affinity illudofulvene conjugates | AF CHEMICALS LLC (US) | 2023-02-28 | — | — | US | disclosed |
| US-11576876-B2 | Affinity Medicant Conjugate | AF CHEMICALS, LLC (US) | 2023-02-14 | — | — | US | disclosed |
| US-20220213452-A1 | CONDITIONALLY ACTIVE HETERODIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-07-07 | — | — | US | disclosed |
| US-20220133649-A1 | AFFINITY MEDICANT CONJUGATE | Califia Pharma Inc. (US) | 2022-05-05 | — | — | US | disclosed |
| US-11254924-B2 | Method for biocatalysis using filamentous fungi | THE UNIVERSITY OF THE WEST INDIES (JM) | 2022-02-22 | — | — | US | disclosed |
| US-11241398-B2 | Affinity medicant conjugate | AF CHEMICALS, LLC (US) | 2022-02-08 | — | — | US | disclosed |
| US-20220008361-A1 | AFFINITY MEDICANT CONJUGATE | Califia Pharma Inc. (US) | 2022-01-13 | — | — | US | disclosed |
| EP-2093285-A1 | Method for biocatalysis using filamentous fungi | The University of the West Indies (JM) | 2009-08-26 | — | — | EP | disclosed |
| US-20080075772-A1 | PHARMACEUTICAL COMPOSITIONS HAVING NOVEL SCORING PATTERNS AND METHODS OF USING THOSE COMPOSITIONS | ACCU-BREAK TECHNOLOGIES, INC. | 2008-03-27 | — | — | US | disclosed |
| US-20070093460-A1 | Methods of using selective 11beta-HSD inhibitors to treat gluocorticoid associated states | RHODE ISLAND HOSPITAL, THE | 2007-04-26 | — | — | US | disclosed |
| US-5804576-A | CANCER PREVENTIVE AGENTS, ANTI-OBESITY AGENTS, TREATMENT OF DIABETES | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1998-09-08 | — | — | US | disclosed |
| US-5714481-A | ADMINISTERING TO MAMMALIAN HOST A GLUCOSE-6-PHSOPHATE DEHYDROGENASE INHIBITOR, ANTICARCINOGENIC, ANTIOBASITY, ANTI-HYPERGLYCEMIC, ANTIAGING, ANTICHOLESTEROL AND ANTI-AUTOIMMUNE AGENT | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1998-02-03 | — | — | US | disclosed |
| EP-0133995-B1 | STEROIDS AND THERAPEUTIC COMPOSITIONS CONTAINING SAME | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1992-04-15 | — | — | EP | disclosed |
| US-5001119-A | 16-substituted androstanes and 16-substituted androstenes | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 1991-03-19 | — | — | US | disclosed |
| US-4898694-A | 17-Hydroxy-steroids | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 1990-02-06 | — | — | US | disclosed |
| US-4874696-A | FROM ALCALIGENES; MEDICAL DIAGNOSIS | THE JOHNS HOPKINS UNIVERSITY, MED SCHOOL (US) | 1989-10-17 | — | — | US | disclosed |
| US-4013688-A | STEROIDS | THE UPJOHN COMPANY (US) | 1977-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212113-A1 | AFFINITY ILLUDOFULVENE CONJUGATES | OGFR, TNFSF11, FCER2 | SMN1; SMN2 2596/4885NR3C2 3284/4885HSD11B2 4541/4885 |
| US-20070093460-A1 | Methods of using selective 11beta-HSD inhibitors to treat gluocorticoid associated states | HSD11B2, HSD11B1, HSD17B2 | SMN1; SMN2 2298/4885NR3C2 16/4885HSD11B2 1/4885 |
| US-20230372267-A1 | AFFINITY MEDICANT CONJUGATE | FCER2, HDGF, FCGR2A | SMN1; SMN2 3267/4885NR3C2 606/4885HSD11B2 1744/4885 |
| US-20220133649-A1 | AFFINITY MEDICANT CONJUGATE | FCER2, HDGF, FCGR2A | SMN1; SMN2 3267/4885NR3C2 606/4885HSD11B2 1744/4885 |
| US-11591295-B2 | Affinity illudofulvene conjugates | OGFR, TNFSF11, FCER2 | SMN1; SMN2 2596/4885NR3C2 3284/4885HSD11B2 4541/4885 |
| US-20220213452-A1 | CONDITIONALLY ACTIVE HETERODIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF | CPB2, AGBL2, IAPP | SMN1; SMN2 2892/4885NR3C2 4062/4885HSD11B2 4022/4885 |
| US-11576876-B2 | Affinity Medicant Conjugate | FCER2, HDGF, FCGR2A | SMN1; SMN2 3267/4885NR3C2 606/4885HSD11B2 1744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.